What is the appropriate cloxacillin dosing regimen for an adult with end‑stage renal disease (eGFR < 15 mL/min/1.73 m²) undergoing intermittent hemodialysis?

Cloxacillin Dosing in End-Stage Renal Disease on Hemodialysis

For adults with ESRD (eGFR < 15 mL/min/1.73 m²) on intermittent hemodialysis requiring cloxacillin, use standard doses without reduction, but extend the dosing interval and administer immediately after hemodialysis sessions.

Dosing Recommendations

Based on the penicillin class characteristics and renal dosing principles, cloxacillin should be dosed as follows:

• Standard dose per administration: Maintain full therapeutic doses (typically 1-2 g per dose for serious infections)
• Frequency adjustment: Reduce from every 6 hours to every 48-72 hours, aligned with hemodialysis schedule
• Timing: Administer immediately after each hemodialysis session (typically 3 times per week)

Rationale and Key Principles

The penicillin class, including cloxacillin, exhibits concentration-dependent bactericidal activity 1. The KDOQI guidelines specifically note that penicillins carry risks of crystalluria and neurotoxicity (particularly benzylpenicillin) when eGFR < 15 mL/min/1.73 m² with high doses, with a maximum recommended dose of 6 g/day for benzylpenicillin 1.

Critical dosing principle: Do not reduce the milligram dose per administration—instead, extend the interval between doses. Smaller doses may compromise efficacy for concentration-dependent antibiotics. This principle is explicitly stated for aminoglycosides and other concentration-dependent agents in ESRD 2.

Timing Relative to Dialysis

Post-dialysis administration serves three purposes:

1. Facilitates directly observed therapy when dosing 3 times weekly 2
2. Prevents premature drug removal before adequate tissue distribution 2
3. Avoids underdosing that could result from dialytic clearance 2

Beta-lactams like cloxacillin have relatively low molecular weights and limited protein binding, making them dialyzable. Research on related penicillins (dicloxacillin, flucloxacillin) confirms significant alterations in elimination kinetics during hemodialysis 3.

Monitoring and Safety Considerations

Nephrotoxicity Risk

Recent data show cloxacillin-associated acute kidney injury (AKI) occurs in 12.8-19.8% of patients, particularly with:

• High doses (≥10-12 g/day) 4, 5
• Elderly patients 5
• Concomitant nephrotoxic drugs (aminoglycosides, diuretics, ACE inhibitors) 5

In ESRD patients already on dialysis, nephrotoxicity is less relevant as renal function is already absent. However, monitor for:

• Hepatotoxicity (abnormal liver function tests occur in ~35% of AKI cases) 5
• Hypereosinophilia (13% of cases) 5
• Neurological symptoms if doses exceed 6 g/day 1

Therapeutic Drug Monitoring

While not routinely available for cloxacillin, consider monitoring if available, particularly since 57% of patients with AKI had plasma concentrations >50 µg/mL 5. For related beta-lactams, maintaining time above MIC (T>MIC) of 100% optimizes outcomes in severe infections 6.

Common Pitfalls to Avoid

1. Do not reduce dose per administration—this compromises concentration-dependent killing
2. Do not dose before dialysis—this wastes drug through dialytic removal
3. Do not use daily dosing—accumulation will occur without renal clearance
4. Do not combine with aminoglycosides without careful monitoring—synergistic nephrotoxicity risk 5
5. Do not exceed 6 g total daily dose due to neurotoxicity risk in severe renal impairment 1

Alternative Considerations

If cloxacillin is being used for methicillin-susceptible Staphylococcus aureus (MSSA) infections, consider that lower doses (8 g/24h median) are associated with significantly lower AKI rates (12.8% vs 19.8%) while maintaining efficacy 4. In ESRD patients, a regimen of 1-2 g three times weekly post-dialysis balances efficacy with safety.

For patients with residual renal function (eGFR 15-30 mL/min/1.73 m²) not yet on dialysis, dose adjustments should be more conservative, potentially using twice-weekly dosing with close monitoring.